CDKN2A and breast carcinoma: Here, we demonstrate that the elimination of senescent (p16+) cells by a genetic approach [42] ameliorates the efficacy of P→RT (without a significant effect on RT→P) in an immunocompetent model that recapitulates key immunobiological features of human HR+ breast cancer.